0001140361-16-056099.txt : 20160302 0001140361-16-056099.hdr.sgml : 20160302 20160302171431 ACCESSION NUMBER: 0001140361-16-056099 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20160301 ITEM INFORMATION: Other Events FILED AS OF DATE: 20160302 DATE AS OF CHANGE: 20160302 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PharMerica CORP CENTRAL INDEX KEY: 0001388195 STANDARD INDUSTRIAL CLASSIFICATION: RETAIL-DRUG STORES AND PROPRIETARY STORES [5912] IRS NUMBER: 870792558 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-33380 FILM NUMBER: 161478289 BUSINESS ADDRESS: STREET 1: 1901 CAMPUS PLACE CITY: LOUISVILLE STATE: KY ZIP: 40299 BUSINESS PHONE: 502.627.7000 MAIL ADDRESS: STREET 1: 1901 CAMPUS PLACE CITY: LOUISVILLE STATE: KY ZIP: 40299 FORMER COMPANY: FORMER CONFORMED NAME: SAFARI HOLDING CORP DATE OF NAME CHANGE: 20070130 8-K 1 form8k.htm PHARMERICA CORPORATION 8-K 3-1-2016
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
FORM 8-K
 
 
CURRENT REPORT
Pursuant to Section 13 OR 15(d)
of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 1, 2016
 

PHARMERICA CORPORATION
(Exact Name of Registrant as Specified in Its Charter)
 

Delaware
  
001-33380
  
87-0792558
         
(State or Other Jurisdiction
of Incorporation)
  
(Commission
File Number)
  
(IRS Employer
Identification No.)

1901 Campus Place
Louisville, Kentucky 40299
(Address of principal executive offices) (Zip Code)

(502) 627-7000
(Registrant’s telephone number, including area code)
 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 

Item 8.01 Other Matters.

As we have previously disclosed, we received a comment letter from the Securities and Exchange Commission ("SEC") Division of Corporate Finance, dated November 24, 2015 with respect to our Annual Report on Form 10-K for the year ended December 31, 2014 and our Quarterly Report on Form 10-Q for the quarter ended September 30, 2015 (collectively, the “Reviewed Filings”). We submitted a response to that initial comment letter and received follow-up comments and submitted responses to the follow-up comments.  As of the date of the filing of our Annual Report on Form 10-K for the year ended December 31, 2015, we believed that the only comments that remained open related to our accounting for the $71.5 million receivable from AmerisourceBergen Drug Company (“ABDC”) as of September 30, 2015 and the withholding of approximately $48.8 million of normal recurring payments due to ABDC.  On March 1, 2016, we received a letter from the Staff of the SEC stating that they have completed their review of the Reviewed Filings.
 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
PHARMERICA CORPORATION
     
Date: March 2, 2016
By:
/s/ Thomas A. Caneris
   
Thomas A. Caneris
   
Senior Vice President, General Counsel, and Secretary